- 注册
- 2005-11-23
- 消息
- 30,365
- 荣誉分数
- 7,477
- 声望点数
- 373
8 min ago
Moderna chief medical officer says chances of Covid-10 vaccine working is "pretty good"
From CNN's Leinz Vales
Moderna Therapeutics headquarters is seen here in Cambridge, Massachusetts. Blake Nissen/The Boston Globe /Getty Images
Moderna's chief medical officer said Wednesday that he's "cautiously optimistic" about the biotechnology company's Covid-19 vaccine developed in partnership with the National Institutes of Health.
Zaks insisted that an independent body of experts will continue to monitor the study as it enters a large phase three trial — the final trial stage before regulators consider whether to make the vaccine available.
Moderna chief medical officer says chances of Covid-10 vaccine working is "pretty good"
From CNN's Leinz Vales
Moderna Therapeutics headquarters is seen here in Cambridge, Massachusetts. Blake Nissen/The Boston Globe /Getty Images
Moderna's chief medical officer said Wednesday that he's "cautiously optimistic" about the biotechnology company's Covid-19 vaccine developed in partnership with the National Institutes of Health.
The results, published in the New England Journal of Medicine on Tuesday, showed that the vaccine worked to trigger an immune response with mild side effects — fatigue, chills, headache, muscle pain, pain at the injection site — becoming the first US vaccine candidate to publish results in a peer-reviewed medical journal.“We believe that the chances of this working are pretty good," said Dr. Tal Zaks, chief medical officer for Moderna. "And the reasons are that the ability to neutralize antibodies to mediate the right immune response I think has been demonstrated for other similar viruses and in preclinical models."
Zaks insisted that an independent body of experts will continue to monitor the study as it enters a large phase three trial — the final trial stage before regulators consider whether to make the vaccine available.
"I feel very confident you're not going to have to trust me on this, there will be the right appropriated body of experts that will look at the data as it emerges to ascertain indeed the benefit risk profile warrants deployment," Zaks said.